Rubric Capital Management (New York)’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $22.6M | Buy |
1,294,878
+265,777
| +26% | +$4.64M | 0.34% | 46 |
|
|
2025
Q1 | $12.9M | Buy |
+1,029,101
| New | +$12.9M | 0.23% | 49 |
|
|
2024
Q3 | – | Sell |
-639,203
| Closed | -$5.44M | – | 73 |
|
|
2024
Q2 | $5.44M | Hold |
639,203
| – | – | 0.14% | 59 |
|
|
2024
Q1 | $6.53M | Hold |
639,203
| – | – | 0.19% | 60 |
|
|
2023
Q4 | $3.5M | Hold |
639,203
| – | – | 0.07% | 53 |
|
|
2023
Q3 | $2.42M | Sell |
639,203
-2,160,000
| -77% | -$8.16M | 0.09% | 58 |
|
|
2023
Q2 | $18.8M | Sell |
2,799,203
-681,509
| -20% | -$4.57M | 0.8% | 37 |
|
|
2023
Q1 | $22.7M | Buy |
3,480,712
+490,148
| +16% | +$3.19M | 0.59% | 39 |
|
|
2022
Q4 | $25.5M | Buy |
2,990,564
+295,394
| +11% | +$2.52M | 1.11% | 30 |
|
|
2022
Q3 | $14.2M | Buy |
2,695,170
+1,708,717
| +173% | +$9.02M | 0.72% | 38 |
|
|
2022
Q2 | $4.18M | Buy |
+986,453
| New | +$4.18M | 0.22% | 67 |
|